- Home
- ROIV vs CELH Comparison
ROIV vs CELH Comparison
Compare ROIV & CELH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROIV
- CELH
- Stock Information
- Founded
- ROIV 2014
- CELH 2004
- Country
- ROIV United Kingdom
- CELH United States
- Employees
- ROIV N/A
- CELH N/A
- Industry
- ROIV Biotechnology: Pharmaceutical Preparations
- CELH Beverages (Production/Distribution)
- Sector
- ROIV Health Care
- CELH Consumer Staples
- Exchange
- ROIV Nasdaq
- CELH Nasdaq
- Market Cap
- ROIV 8.6B
- CELH 15.7B
- IPO Year
- ROIV N/A
- CELH N/A
- Fundamental
- Price
- ROIV $16.99
- CELH $63.10
- Analyst Decision
- ROIV Strong Buy
- CELH Strong Buy
- Analyst Count
- ROIV 8
- CELH 18
- Target Price
- ROIV $19.94
- CELH $62.61
- AVG Volume (30 Days)
- ROIV 7.5M
- CELH 5.3M
- Earning Date
- ROIV 11-11-2025
- CELH 11-05-2025
- Dividend Yield
- ROIV N/A
- CELH N/A
- EPS Growth
- ROIV N/A
- CELH N/A
- EPS
- ROIV N/A
- CELH 0.39
- Revenue
- ROIV $23,233,000.00
- CELH $1,666,480,000.00
- Revenue This Year
- ROIV N/A
- CELH $84.05
- Revenue Next Year
- ROIV $200.91
- CELH $29.58
- P/E Ratio
- ROIV N/A
- CELH $159.86
- Revenue Growth
- ROIV N/A
- CELH 11.85
- 52 Week Low
- ROIV $8.73
- CELH $21.10
- 52 Week High
- ROIV $17.13
- CELH $64.81
- Technical
- Relative Strength Index (RSI)
- ROIV 80.47
- CELH 65.03
- Support Level
- ROIV $15.91
- CELH $59.73
- Resistance Level
- ROIV $16.39
- CELH $64.81
- Average True Range (ATR)
- ROIV 0.50
- CELH 2.29
- MACD
- ROIV -0.00
- CELH 0.45
- Stochastic Oscillator
- ROIV 94.04
- CELH 86.65
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About CELH Celsius Holdings Inc.
Celsius Holdings plays in the energy drink subsegment of the global nonalcoholic beverage market, with 95% of revenue concentrated in North America. The firm now owns three energy drink brands: Celsius, Alani Nu, and Rockstar Energy. It dedicates its efforts to product innovation and marketing while outsourcing manufacturing and packaging to third-party co-packers and distribution to PepsiCo. The firm issued convertible preferred shares following PepsiCo's investments in 2022 and 2025, giving the latter an 11% stake in Celsius.